We analyzed expression data from recent studies in which melanoma patients were treated with immune-checkpoint therapy (ICT)2,31 to determine whether melanoma patient response to ICT is correlated with PSMB8 and PSMB9 levels. The gene discussed is PSMB9; the disease is melanoma.